Vaprisol
AssetAlso called conivaptan, YM-087, CI-1025
Blocks vasopressin V1A and V2 receptors, promoting free-water excretion and reducing vasopressin-mediated vasoconstriction.
- Stage
- Approved
- Modality
- Small molecule
- Target
- AVPR1A
- 9
- Indications
- 15
- Trials
- 1
- Developer
Approved by the FDA on Dec 29, 2005 (NDA021697). 2 approvals stand. FDA
Indications
9Euvolemic and hypervolemic hyponatremia
Approved, cumberlandpharma.com
Acute decompensated heart failure
Phase 3, Terminated, NCT00843986, clinicaltrials.gov, Nov 12, 2026
Euvolemia
Phase 3, Completed, NCT00435591, clinicaltrials.gov, Nov 12, 2026
6 more
In the full profile
- Target and mechanism3
- Owner and partners1
- Trials15
- Evidence for its targets2
- Competitors12
- Signals10
Every asset’s record: target, stage, trials and the evidence behind it.